二甲双胍联合西格列汀或吡格列酮对肥胖型2型糖尿病的疗效比较

目的：比较西格列汀与吡格列酮分别联用二甲双胍治疗二甲双胍单药控制不佳的肥胖型2型糖尿病的疗效。方法：60例2型糖尿病肥胖患者在服用二甲双胍片的前提下，随机分为西格列汀组（n=30）和吡格列酮组（n=30），分别给予西格列汀片与吡格列酮片口服，检测入组时和治疗12周后两组糖化血红蛋白、空腹及餐后血糖水平、低血糖例数、体重指数等数据。结果：治疗12周后，西格列汀组患者的糖化血红蛋白、空腹及餐后血糖、体重指数均比吡格列酮组改善明显，两组均无低血糖发生。结论：西格列汀联用二甲双胍片治疗肥胖型2型糖尿病的疗效优于吡格列酮片联用二甲双胍片。

Comparing effects on type 2 diabetes of metformin either with sitagliptin or pioglitazone

Objective :To comparing efficacy differences combined with metformin between sitagliptin and pioglitazone on obese type 2 diabetes mellitus that had a poorly control with metformin monotherapy. Methods:60 cases of obese patients with type 2 diabetes mellitus in the premise of using metformin were randomly divided into sitagliptin group(n=30)and pioglitazone group(n=30). Medical data such as Glycosylated hemoglobin,fasting and postprandial blood glucose level, the number of cases of hypoglycemia, BMI were recorded before grouping and after a treatment of 12 weeks,. Results:Glycosylated hemoglobin, fasting and postprandial blood glucose levels, BMI levels in patients of sitagliptin group were significantly improved in 12 weeks compared with pioglitazone group. Hypoglycemia did not happen in both group. Conclusion: Combined with metformin, the efficacy of Sitagliptin is better than that of pioglitazone on obese type 2 diabetes mellitus.